Vnitr Lek 2017, 63(11):876-883 | DOI: 10.36290/vnl.2017.160

Small-cell lung cancer: epidemiology, diagnostics and therapy

Miloš Pešek1,*, Jan Mužík2
1 Klinika pneumologie a ftizeologie LF UK a FN Plzeň
2 ÚZIS Praha

Authors present actual overview of information on diagnostic and therapeutic procedures in small-cell lung cancer (SCLC). This highly aggressive type of lung cancer is diagnosed in 14.8 % of Czech lung cancer patients. Vast majority of those patients (87 %) suffer from advanced and metastatic disease in the time of diagnosis. In this issue are presented prognostic factors, staging diagnostic procedures and therapeutic recommendations. The backbone of actual SCLC treatment is combined chemotherapy and radiotherapy and less frequently, carefully in selected cases, surgical procedures. SCLC should be have as chemosensitive, chemoresistent or chemorefractory disease. Actual cytostatic combinations used in 1st line treatment, different schedules of chemoradiotherapy, drugs used in second line treatment and schedules and timing of prophylactic brain irradiation are presented. In near future, perspectively, there are some promissible data on antitumour immunotherapy based on anti CTLA-4 and anti PD-1/PE-L1 antibodies also in SCLC patients.

Keywords: cancer immunotherapy; concomitant chemoradiotherapy; chemotherapy; chest radiotherapy; lung resections; prophylactic brain irradiation; small cell lung cancer

Received: September 4, 2017; Accepted: September 26, 2017; Published: November 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pešek M, Mužík J. Small-cell lung cancer: epidemiology, diagnostics and therapy. Vnitr Lek. 2017;63(11):876-883. doi: 10.36290/vnl.2017.160.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Almquist D, Mosalpuria K, Ganti AK Multimodality Therapy for Limited-Stage Small-Cell LungCancer. J Oncol Pract 2016; 12(2): 111-117. Dostupné z DOI: <http://dx.doi.org/10.1200/JOP.2015.009068>. Go to original source... Go to PubMed...
    2. Corso CD, Rutter CE, Park HS et al. Role of Chemoradiotherapy in Elderly Patients With Limited-Stage Small-Cell Lung Cancer. J Clin Oncol 2015; 33(36): 4240-4246. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2015.62.4270>. Go to original source... Go to PubMed...
    3. Fan M, Zhang J, Liu D et al. Comparison of PET/CT, 99mTc-MDP Bone Scan and Serum Alkaline Phosphatase for Detecting Bony Metastasis in Patients with Small Cell Lung Cancer. J Thorac Oncol 2015; 10(Suppl 2): S501. P1.07-016.
    4. George J, Lim JS, Jang JS et al. Comprehensive genomic profiles of small cell lung cancer. Nature 2015; 524(7563): 47-53. Dostupné z DOI: <http://dx.doi.org/10.1038/nature14664>. Go to original source... Go to PubMed...
    5. Hanna N, Bunn PA, Langer C et al. Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer. J Clin Oncol 2006; 24(13): 2038-2043. Go to original source... Go to PubMed...
    6. Hermes A, Bergman B, Bremnes R et al. Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin in Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial. J Clin Oncol 2008; 26(26): 4261-4267. Dostupné z DOI: <http://dx.doi.org/10.1200/JCO.2007.15.7545>. Go to original source... Go to PubMed...
    7. Illei PB, Forde P, Hann C et al. Expression in Small Cell Lung Carcinoma: An Immunohistochemical Analysis of 26 Cases Using Two Anti-PD-L1 Antibodies. J Thorac Oncol 2015; 10(Suppl 2): S360.
    8. Ishii H, Azuma K, Kawahara A et al. Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer. J Thorac Oncol 2015; 10(3): 426-430. Dostupné z DOI: <http://dx.doi.org/10.1097/JTO.0000000000000414>. Go to original source... Go to PubMed...
    9. Kim EY, Kim YS, Park I et al. Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer. J Thorac Oncol 2015; 10(12): 1795-1799. <http://dx.doi.org/10.1097/JTO.0000000000000690>. Go to original source... Go to PubMed...
    10. Kolek V et al. Doporučené postupy v pneumologii. Maxdorf: Praha: 2013. ISBN 978-80-7345-359-6.
    11. Mamdani H, Induru R, Jalal SI. Novel therapies in small cell lung cancer. Review Article on Lung Cancer Diagnostics and Treatments 2015: A Ranaissance of Patient Care. Transl Lung Cancer Res 2015; 4(5): 533-544. Dostupné z DOI: <http://dx.doi.org/10.3978/j.issn.2218-6751.2015.07.20>.
    12. Nawal L, Islam KMM, Deviany PE et al. Survival Trends of Small Cell Lung Cancer (SCLC) in the United States: A SEER Database Analysis. J Thorac Oncol 2015; 10(Suppl.2): S402.
    13. Ott P, Felip E, Hiret S et al. OA05.01 pembrolizumab in patients with extensive-stage small cell lung cancer: Updated survival results from KEYNOTE-028. J Thorac Oncol 2017; 12(1 Suppl): S259. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jtho.2016.11.250>. Go to original source...
    14. Pillai RN, Owonikoko TK. Small Cell Lung Cancer: Therapies and targets. Semin Oncol 2014; 41(1): 133-142. Dostupné z DOI: <http://dx.doi.org/10.1053/j.seminoncol.2013.12.015>. Go to original source... Go to PubMed...
    15. Rudin CM, Pietanza MC, Spigel DR et al. A DLL3-Targeted ADC, Rovalpituzumab Tesirine, Demonstrates Substantial Activity in a Phase I Study in Relapsed and Refractory SCLC. J Thorac Oncol 2015; 10(Suppl 2): S192.
    16. Slotman B, Faivre-Finn C, Tinteren HV et al. Which Patients with ES-SCLC Should Receive Thoracic Radiotherapy (TRT) Routinely? J Thorac Oncol 2015; 10(Suppl 2): S193.
    17. Sobin LH, Gospodarowicz MK, Wittekind C. TNM - klasifikace zhoubných novotvarů. 7. ed. UICC - International Union Against Cancer, global cancer control 2009. Česká verze 2011. ISBN 978-80-904259-6-5.
    18. Stinchcombe TE Current Treatments for Surgically Resectable, Limited-Stage, and Extensive-Stage Small Cell Lung Cancer. Oncologist 2017; pii: theoncologist.2017-0204. Dostupné z DOI: <http://dx.doi.org/10.1634/theoncologist.2017-0204>. Go to original source... Go to PubMed...
    19. Thomas A, Szabo E, Pinsky P. Screening for Small Cell Lung Cancer: Analysis of the National Lung Cancer Screening Trial Data. J Thorac Oncol 2015; 10(Ssuppl 2): S221. Abstract ORAL25.01.
    20. Vandeusen A, Zaidi AH, Martin SA et al. "Peripheral Limited" Small Cell Lung Cancer (SCLC). Does Surgical Resection Have a Role in Primary Management? J Thorac Oncol 2015; 10(Ssuppl 2): S499.
    21. Videtic GM, Reddy C, Woody N et al. Medically Inoperable Early Stage Small Cell Lung Cancer: Patterns of Failure after SBRT. J Thorac Oncol 2015; 10(Suppl 2): S626. Go to original source...
    22. Wong AT, Rineer J, Schwartz D et al. Assessing the Impact of Postoperative Radiation Therapy for Completely Resected Limited-Stsage Small Cell Lung Cancer Using the National Cancer Database. J Thorac Oncol 2015; 11(2): 242-248. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jtho.2015.10.011>. Go to original source... Go to PubMed...
    23. Xie D, Marks R, Zhang M et al. Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers. J Thorac Oncol 2015; 10(8): 1213-1220. Dostupné z DOI: <http://dx.doi.org/10.1097/JTO.0000000000000585>. Go to original source... Go to PubMed...
    24. Yang ChFJ, Chan DY, Speicher PJ et al. Long-Term Survival after Surgery for Pathologic N1 and N2 Small Cell Lung Cancer: A Comparison with Nonoperative Management. J Thorac Oncol 2015; 10(Suppl 2): S193.
    25. Informace dostupné z WWW: <http://www.uzis.cz>

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.